Safety and Tolerability of Adoptive Cell Therapy in Cancer.

Détails

Ressource 1Télécharger: 30649750AM.pdf (1233.33 [Ko])
Etat: Public
Version: Author's accepted manuscript
Licence: Tous droits réservés
ID Serval
serval:BIB_944ED4AF4291
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Safety and Tolerability of Adoptive Cell Therapy in Cancer.
Périodique
Drug safety
Auteur(s)
Wolf B., Zimmermann S., Arber C., Irving M., Trueb L., Coukos G.
ISSN
1179-1942 (Electronic)
ISSN-L
0114-5916
Statut éditorial
Publié
Date de publication
02/2019
Peer-reviewed
Oui
Volume
42
Numéro
2
Pages
315-334
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection. In recent years, some ACTs have produced unprecedented breakthrough responses: TIL therapy has moved from melanoma to solid tumor applications, TCR-engineered cells are developed for hematologic and solid tumors, and CAR-engineered T cells have received Food and Drug Administration (FDA) approval for the treatment of patients with certain B-cell malignancies. Although results are encouraging, to date, only a small percentage of patients with advanced malignancies can benefit from ACT. Besides ACT availability and accessibility, treatment-related toxicities represent a major hurdle in the widespread implementation of this therapeutic modality. The large variety of observed toxicities is caused by the infused cell product or as side effects of accompanying medication and chemotherapy. Toxicities can occur immediately or can be delayed. In order to render those highly promising therapeutic approaches safe enough for a wider pool of patients outside of clinical trials, an international consensus for toxicity management needs to be established.
Mots-clé
Animals, Antineoplastic Agents/adverse effects, Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Clinical Trials as Topic/methods, Humans, Immunotherapy, Adoptive/adverse effects, Immunotherapy, Adoptive/methods, Neoplasms/drug therapy, Neoplasms/immunology, Neoplasms/metabolism, Nervous System Diseases/chemically induced, Nervous System Diseases/metabolism, T-Lymphocytes/drug effects, T-Lymphocytes/immunology, T-Lymphocytes/metabolism
Pubmed
Web of science
Création de la notice
08/02/2019 13:50
Dernière modification de la notice
20/08/2019 15:56
Données d'usage